Are Weight Loss Injections Safe on the NHS and Privately?

Step 1: How these medicines were assessed before reaching UK patients

Before either Mounjaro or Wegovy reached a single UK patient, the MHRA scrutinised trial data from large, controlled studies. SURMOUNT-1, for example, randomised 2,539 adults to tirzepatide or placebo over 72 weeks and tracked not just weight loss but cardiovascular markers, liver enzymes, and adverse events throughout. Semaglutide went through an equally rigorous process, including the STEP 1 trial published in the New England Journal of Medicine. NICE then ran its own independent health technology appraisals (TA875 for Wegovy and TA1026 for Mounjaro) before recommending either for NHS use, and if you are wondering specifically about accessing a weight loss injection on the NHS, that appraisal process is what determines which patients qualify and under what conditions. That two-layer regulatory and clinical review process is why these medicines are classed as prescription-only: the evidence supports their use, but only within a supervised clinical framework. You can read more about the overall landscape of weight loss injections in the UK to see how both fit together.

The MHRA also places both medicines under Black Triangle (▼) status, meaning healthcare professionals and patients are encouraged to report suspected side effects, an ongoing safety surveillance layer that continues after approval.

Step 2: The side effects to expect, and the ones to take seriously

If you are feeling a little apprehensive about starting, that is completely understandable. These are injectable medicines with a noticeable effect on appetite and digestion, and the prospect of side effects puts most people on edge before their first dose.

The most common effects (nausea, loose stools, constipation, indigestion, burping and occasional fatigue) are linked to how GLP-1 medicines slow the movement of food through your stomach. They tend to be most noticeable in the first week or two after starting, or after a dose increase, and most people find they ease considerably once their body adjusts. Injection-site reactions (mild redness or tenderness) are also reported but rarely troublesome. The NHS medicines page for tirzepatide lists these in plain language and is worth bookmarking alongside your patient information leaflet.

Then there are rarer but more serious effects that warrant prompt attention. Gallbladder problems can develop with longer-term use. Significant dehydration from persistent vomiting or diarrhoea can strain the kidneys. Allergic reactions, though uncommon, can escalate quickly. Our treatment consultation page covers how our prescribers discuss these risks with patients individually before anything is prescribed.

Step 3: When to get medical help without waiting

In January 2026, the MHRA published a Drug Safety Update specifically flagging acute pancreatitis as a known (if infrequent) risk with GLP-1 medicines. The symptom to act on is severe, persistent pain in your abdomen, particularly if it radiates through to your back, with or without vomiting. That is a 999 or same-day emergency call, not a 'wait and see'.

Other symptoms that need prompt medical attention include signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing), jaundice or upper-right abdominal pain that might suggest gallbladder involvement, or symptoms of severe dehydration, dizziness, very dark urine, no urination for hours. If you are on insulin or another diabetes medicine alongside a GLP-1, low blood sugar is an additional risk to know about.

If you experience anything you are unsure about, the right move is to contact your prescribing service or GP, not to stop treatment abruptly without guidance. You can also report suspected side effects directly through the MHRA's Yellow Card scheme, the reporting system exists precisely so that signals from real-world use feed back into ongoing safety monitoring. Details of what to watch for are covered further on our page on injection safety for NHS patients.

Step 4: Where you get the medicine is part of the safety calculation

The medicine itself is only part of the picture. A genuine, properly stored pen prescribed after a clinical assessment is a very different proposition from a pen that arrived from an unverified seller via social media. The MHRA has seized approximately 20 million doses of illegally traded weight loss medicines (worth around £45 million) and in October 2025 raided a site in Northampton that was producing counterfeit tirzepatide pens. Some fake pens have contained insulin, which without medical supervision can cause life-threatening hypoglycaemia.

The one check that costs nothing and matters enormously: look up any online pharmacy on the GPhC register before ordering. A registered pharmacy has a premises number you can verify, nume's is 9012878. If a seller cannot give you that, or offers these medicines without a clinical assessment, do not proceed. If you have questions about how weight loss injections work through the NHS, including what the referral process involves, our dedicated page explains the pathway in full. And if you are unsure whether you qualify, our eligibility guide sets out the NHS and private criteria clearly.

Our prescribers go through suitability, side effects and your personal health history as part of every consultation, not as a tick-box, but as the actual clinical review. If you would like to explore your treatment options, or want a clear answer to the question of whether weight loss injections are safe on the NHS before committing to anything, speaking to a prescriber is the right first step.